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Identity 
Other names: BCL2L4 
HGNC (Hugo): BAX  
Location: 19q13.33 
Local order: Orientation: Plus Strand. 
DNA/RNA 
Description 
The BAX gene, with 6.939 bases in length, consists of 
6 exons and 5 intervening introns. 
Transcription 
The BAX gene is characterized by 5 protein coding 
transcripts (alpha/psi, beta, delta, epsilon, sigma). B x-
beta encodes the longest isoform (891 bp) of the gene. 
BAX-alpha/Bax-psi variant is 888 bp in length and 
codes for a protein isoform that possesses a shorter and 
different C terminus, as compared with the isoform 
BAX-beta. The third variant (BAX-delta), which is 741 
bp in length, lacks exon 3, whereas it retains the 
functionally critical C-terminal membrane anchorage 
region, as well as the BCL2 homology 1 and 2 (BH1 
and BH2) domains, although it has a shorter and 
different C terminus, in comparison with BAX-beta. 
The fourth identified variant of BAX, which is 
designated as BAX-epsilon, is 986 bp in length because 
it contains an extra fragment within the coding region, 
as well as a distinct 3' coding region and 3' UTR, 
resulting in a distinct BAX isoform with a shorter and 
distinct C terminus, as compared with BAX-beta. The 
fifth identified variant of BAX, BAX-sigma, is 849 bp 
in length and has also a shorter and different C 
terminus, when compared with the isoform beta. 
Pseudogene 
Not identified so far. 
Protein 
Note 
The BAX gene encodes for a 21 kDa protein, named 
BAX-alpha. It was the first death-inducing member of 
the BCL2 family to be identified, and it was detected as 
a protein co-purified with BCL2 in 
immunoprecipitation studies. The BH3 domain of BAX 
is essential for its homodimerization and its 
heterodimerization with BCL2 and BCL-XL. 
Furthermore, the protein contains a hydrophobic C-
terminal region essential for membrane targeting, while 
BH1 and BH2 domains show homology to pore-
forming proteins that contribute to apoptosis. In 
addition to BAX-alpha, which is the major protein 
product of the whole gene, BAX undergoes alternative 
splicing, resulting in the production of distinct protein 
isoforms. The tumour suppressor p53 is a 
transcriptional regulator of BAX, since the promoter of 
the BAX gene possesses four regions with high 
homology to the consensus p53 binding sites. 
Description 
The BAX belongs to the BCL2 family of proteins. It is 
composed of 192 amino acids (21184 kDa), with a 
calculated molecular mass of 21.184 kDa. The BAX 
protein exists as a monomer, a homodimer, or as a 
heterodimer with BCL2, E1B 19K protein, BCL2L1 
isoform Bcl-X(L), MCL1 and BCL2A1/A1. It also 
interacts with SH3GLB1 and HN. It contains one BH3 
homology domain. 
Localisation 
BAX protein has been reported to be localized in the 
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mitochondria, mitochondrial permeability transition 
pore complex, mitochondrial outer membrane, 
endoplasmic reticulum membrane and cytoplasm. 
Function 
BAX protein heterodimerizes either with members of 
the BCL2 family of proteins or with tyrosine kinases 
enabling them it to display its proapoptotic function 
within the cell. It is also implicated in the loss of
mitochondrial membrane potential and the release of 
cytochrome c. 
Homology 
Human BAX shares 99.5% amino acid identity with 
Pan troglodytes, 97.4% identity with Canis lupus 
familiaris, 96.4% identity with Bos Taurus, 92.2% 
identity with Mus musculus, 91.2% identity with Rattus 
norvegicus and 52.7% identity with Danio rerio. In 
addition, BAX protein presents high homology to the 
BCL2 protein, containing the conserved regions BH1, 
BH2 and BH3. 
Mutations 
Note 
One regulatory type of mutation has been identified 
according to which a guanine substituting adenosine 
substitution at position 125 (G125A) in the BAX 
promoter is associated with higher stage of chronic 
lymphocytic leukemia (CLL) and failure to respond to 
treatment in CLL patients. Additionally, 110 SNPs, 
with uknown clinical association and the following IDs, 
have been reported in Entrez SNP database: 
rs62125987, rs62125961, rs61473366, rs61415800, 
rs60900019, rs59878749, rs59152877, rs57453473, 
rs57028628, rs56251427, rs56251427, rs55692456, 
rs55692456, rs36101119, rs36096807, rs36017265, 
rs35946201, rs35630245, rs35475300, rs35258702, 
rs34873472, rs34124134, rs34043541, rs28624947, 
rs28450536, rs12983717, rs12976339, rs12976283, 
rs12975003, rs11671610, rs11669164, rs11669162, 
rs11668424, rs11668008, rs11667351, rs11400412, 
rs11358529, rs11302449, rs10644606, rs7508566, 
rs7259013, rs7255991, rs7255559, rs4645904, 
rs4645903, rs4645902, rs4645903, rs4645902, 
rs4645901, rs4645900, rs4645899, rs4645898, 
rs4645897, rs4645896, rs4645895, rs4645894, 
rs4645893, rs4645891, rs4645890, rs4645889, 
rs4645888, rs4645887, rs4645886, rs4645885, 
rs4645884, rs4645883, rs4645882, rs4645881, 
rs4645880, rs4645879, rs4645878, rs4309503, 
rs3817074, rs3817073, rs2387583, rs1985882, 
rs1974820, rs1805419, rs1805418, rs1805417, 
rs1805416, rs1075531, rs1057369, rs1010104, 





Various cancers and diseases 
Disease 
Colorectal cancer, T-cell acute lymphoblastic leu-
kemia, chronic lymphocytic leukemia (CLL), B cell 
chronic lymphocytic leukemia, osteomyelitis. 
Prognosis 
BAX mutations have been found to be associated with
positive prognosis in Dukes B2 patients, concerning 
survival. 
The G(-248)A polymorphism in the promoter region of 
the BAX gene has been associated with reduced BAX 
expression, advanced disease stage, reduced treatment 
response and short overall survival in B-cell chronic 
lymphocytic leukemia (CLL). 
Polymorphisms were found for BAX, caused by 
variation in nucleotide A repeat number at position 360 
in the 5'-region of BAX gene. These allelic frequenci s 
of BAX polymorphism were significantly different 
between males and females and therefore associated 
with gender-based heamatocrite (HCT) differences 
Substitution of the nucleotide G-->A at position -248 in 
the BAX gene was more frequent in patients with 
osteomyelitis and was associated with a longer lifespan 
of their peripheral blood neutrophils, probably 
possessing a significant role in the pathogenesis of 
osteomyelitis. 
In cases of malignancies, the concentration of BAX 
protein in cancer cells is reduced. In addition, p53- 
deficient mice show reduced BAX levels, ultimately 
developing T-cell lymphoma. 
Reduction of BAX expression levels is negatively 
associated with many cancers outcome. It is associated 
with a variety of adverse prognostic factors such as 
poor response to radio- and chemotherapy, advanced 
stage, lymph node metastasis, and reduced disease-free 
and overall survival in variety cancer types, such as 
colorectal, pancreatic, breast, head and neck, prostate, 
small cell lung cancer and gynecological (ovarian) 
malignancies. More specifically, the enhanced 
expression of BAX protein is a positive prognostic 
factor for pancreatic cancer and sensitizes human 
pancreatic cancer cells to apoptosis induced by 
chemotherapeutic agents. In the case of stage II colon 
cancer, treated only with surgery, BAX protein 
expression may be a predictor for prognosis. In ovarian 
cancer, BAX protein may have a predictive potential in 
taxane-platinum-treated patients. Moreover, in resected 
non-small cell lung cancer, low expression of BAX 
implies poor prognosis. In addition, in patients with 
advanced esophageal cancer, treated with  
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chemoradiotherapy, reduced expression levels of BAX 
predict poor prognosis. Low expression of BAX was 
also 
significantly associated with poor PFS and OS in 
nasopharyngeal cancer patients. 
In lung cancer, BAX is translocated to the nucleus, 
enhancing tumour development. Furthermore, 
mutational analysis of the gene in cases of lung cancer 
patients revealed the presence of a silent point mutation 
in codon 184 (TCG>TCA), as well as intronic 
mutations. 
In T cells and endometrium of patients with acute 
lymphoblastic leukaemia, frameshift mutations have 
been detected in the BAX gene. 
It is a common observation in cases of gastrointesti al 
cancer, the detection of two specific missense 
mutations of the BAX gene in codon 169 (Thr > Ala or 
Thr > Met), which cause inhibition of the proapoptotic 
activity of the protein and enhance the development of 
cancer. 
Various chemotherapeutic treatments act via up-
regulation of the BAX gene to block tumour 
progression. 
BAX is highly expressed in HL-60 but it was found to 
be hardly expressed in HL-CR cells, a C2-ceramide-
resistant HL-60 subline, which has been recently 
established. These cells showed reduced response to a 
variety of anticancer drugs including ceramide, 
doxorubicin, etoposide and cytosine arabinoside. 
Hybrid/Mutated gene 
Not identified so far. 
Abnormal protein 
Not identified so far. 
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